OPKO Health Inc
NASDAQ:OPK

Watchlist Manager
OPKO Health Inc Logo
OPKO Health Inc
NASDAQ:OPK
Watchlist
Price: 1.58 USD 1.28% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
OPKO Health Inc?
Write Note

OPKO Health Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OPKO Health Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
OPKO Health Inc
NASDAQ:OPK
Cost of Revenue
-$532.9m
CAGR 3-Years
24%
CAGR 5-Years
2%
CAGR 10-Years
-27%
Abbvie Inc
NYSE:ABBV
Cost of Revenue
-$18.2B
CAGR 3-Years
-1%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Cost of Revenue
-$6.3B
CAGR 3-Years
-5%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cost of Revenue
-$12.9B
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cost of Revenue
-$1.5B
CAGR 3-Years
-20%
CAGR 5-Years
-25%
CAGR 10-Years
-36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cost of Revenue
-$1.8B
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-25%
No Stocks Found

OPKO Health Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 5,767 full-time employees. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. The company also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.

OPK Intrinsic Value
1.82 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is OPKO Health Inc's Cost of Revenue?
Cost of Revenue
-532.9m USD

Based on the financial report for Sep 30, 2024, OPKO Health Inc's Cost of Revenue amounts to -532.9m USD.

What is OPKO Health Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-27%

Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for OPKO Health Inc have been 24% over the past three years , 2% over the past five years , and -27% over the past ten years .

Back to Top